Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis

ABSTRACT: Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis

PROVIDER: PRJNA781833 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Peritoneal Carcinomatosis of gastric cancer

Project description:Peritoneal carcinomatosis is a frequent finding in patients with primary gastric cancer, and it is associated with a poor prognosis. A major mechanism in peritoneal carcinomatosis is the dissemination of cancer cells into the abdominal cavity, mainly in diffuse gastric adenocarcinoma. The features that enable diffuse primary gastric tumours to develop peritoneal dissemination have been little investigated and are only incompletely understood. We therefore compared the gene expression profile in patients with diffuse primary gastric cancer with and without peritoneal carcinomatosis. Specimens from consecutive gastric cancer patients with and without peritoneal carcinomatosis were investigated using oligonucleotide microarrays. Keywords: Disease state analysis

2008-01-31 | GSE8657 | GEO

Expression data of peritoneal carcinomatosis human cell lines co-treated with patient derived ascites and ligand inhibitor

Project description:Characterizations of ascites proteome from ovarian peritoneal carcinomatosis (PC) and gastric PC have demonstrated that ascites contains elevated pro-tumorigenic factors. Reasoning that the composition of ascitic fluid might offer insight into the memory of key biological events occurring intra-abdominally, we hypothesized that paracrine factors essential for survival and growth of peritoneal deposits are secreted into and circulate within ascitic fluid. Our data from cytokine array profile suggest that ascites contains biologically active ligands capable of supporting cellular functions of cancer cells. To decipher downstream signalling pathways activated in cancer cells when exposed to ascites, we performed gene expression analysis of Colo-205 cells upon exposure to PC ascites and ligand inhibitor.

2022-02-22 | GSE189137 | GEO

Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis.

Project description: Not available

| S-EPMC8861959 | biostudies-literature

Ligand-mediated PAI-1 inhibition in a mouse model of peritoneal carcinomatosis

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-02-22 | GSE189169 | GEO

Expression data of peritoneal carcinomatosis human cell lines co-treated with patient derived ascites and ligand inhibitor

Project description:Expression data of peritoneal carcinomatosis human cell lines co-treated with patient derived ascites and ligand inhibitor

| PRJNA781621 | ENA

Proteomics characterization of human peritoneal tissue

Project description:To identify the proteome of human peritoneal tissue, 43 FFPE and 5 fresh frozen peritoneal tissue samples at healthy or non-cancerous state were collected and subjected to mass spectrometry analysis. The resulting findings represnt a baseline catalog of the proteomic composition of the peritoneum, as a comparison dataset for future studies focused on alterations in pathologic states such as peritoneal carcinomatosis.

2025-12-31 | PXD071403 | Pride

Cytokine profile of ascites derived from patients with peritoneal carcinomatosis

Project description:Cytokine profile of ascites derived from patients with peritoneal carcinomatosis

| PRJNA781843 | ENA

Expression data of ascites treated peritoneal carcinomatosis human cell lines

Project description:Expression data of ascites treated peritoneal carcinomatosis human cell lines

| PRJNA781132 | ENA

MVA.scIL12 treatment in a mouse model of peritoneal carcinomatosis (PCa)

Project description:MVA.scIL12 treatment in a mouse model of peritoneal carcinomatosis (PCa)

| PRJNA942622 | ENA

Autocrine Activity of Engineered IL-33 mRNA Enhances Adoptive T Cell Therapy for Peritoneal Carcinomatosis and Synergizes with IL-12 mRNA

Project description:Peritoneal carcinomatosis (PC) remains a significant clinical challenge, with limited therapeutic options. Adoptive cell therapy (ACT) using tumor-specific T cells has emerged as a promising strategy; however, its efficacy is often hindered by the immunosuppressive tumor microenvironment (TME). Interleukin-33 (IL-33), a member of the IL-1 family, plays a dual role in immunity and inflammation, with the potential to enhance antitumor responses. Here, we investigated the impact of IL-33 mRNA-engineered T cells on ACT efficacy in murine models of PC and explored the potential synergy with IL-12 mRNA.

2026-03-06 | GSE291258 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data